Hybio Pharmaceutical Co., Ltd.
300199
Κατάταξη σε μετοχές
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Τιμή μετοχής
$3.69
Κεφαλαιοποίηση
$3.11B
Αλλαγή (1 ημέρα)
-7.75%
Αλλαγή (1 έτος)
21.56%
Χώρα
CN
Εμπόριο Hybio Pharmaceutical Co., Ltd. (300199)
Κατηγορία
Healthcare
EPS για Hybio Pharmaceutical Co., Ltd. (300199)
EPS στις June 2026 TTM: $0.02
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Hybio Pharmaceutical Co., Ltd., το τρέχον EPS της εταιρείας (TTM) είναι $0.02. Στο τέλος του 2024, η εταιρεία είχε EPS $-0.03, μείωση σε σύγκριση με το EPS του 2023 που ήταν $-0.08.
Ιστορικό EPS της Hybio Pharmaceutical Co., Ltd. από 2007 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $0.02 | 110.00% |
| 2025 | $0.01 | -120.80% |
| 2024 | $-0.03 | -66.54% |
| 2023 | $-0.08 | 34.48% |
| 2022 | $-0.06 | -1,207.27% |
| 2021 | $0.01 | -105.21% |
| 2020 | $-0.11 | -26.46% |
| 2019 | $-0.14 | 166.91% |
| 2018 | $-0.05 | -197.29% |
| 2017 | $0.06 | 16.42% |
| 2016 | $0.05 | -9.35% |
| 2015 | $0.05 | 70.68% |
| 2014 | $0.03 | 16.29% |
| 2013 | $0.03 | 50.00% |
| 2012 | $0.02 | 1.15% |
| 2011 | $0.02 | 30.83% |
| 2010 | $0.01 | 51.14% |
| 2009 | $0.01 | 41.94% |
| 2008 | $0.01 | 37.78% |
| 2007 | 0.00 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $6.55 | 31,077.14% |
DE
|
|
| $6.12 | 29,044.76% |
DE
|
|
| $0.72 | 3,343.33% |
JP
|
|
| $3.66 | 17,328.57% |
CH
|
|
| $0.56 | 2,549.05% |
IN
|
